Tools
Granuloma Faciale
Introduction
Granuloma faciale is a rare, benign inflammatory skin disease that usually presents as isolated, well-defined reddish-brown to violaceous asymptomatic papules, nodules, or plaques with follicular accentuation and telangiectasia. This skin disorder was first described as “eosinophilic granuloma” in 1945 by Wigley JE.[1] Granuloma faciale typically affects middle-aged white men but has been reported in individuals ranging from the 2nd to the 7th decade of life. Childhood cases have also been documented.[2][3][4] The condition typically presents as a single lesion on the face, but multiple lesions or extrafacial involvement may also occur.[5] Extrafacial localizations include the scalp, trunk, nasal cavity, or extremities. Facial lesions most frequently appear on the forehead, nose, or cheeks.[6]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The etiology of granuloma faciale is unknown. However, the condition's predilection for sun-exposed areas suggests a possible association with actinic damage. Other proposed contributing factors include allergic hypersensitivity, trauma, and, less commonly, radiation therapy.[7][8]
Epidemiology
Granuloma faciale is a relatively rare condition that primarily affects adults of both sexes, with a slight male predominance. Although all races may be affected, granuloma faciale most commonly occurs in white individuals. The mean age of onset is approximately 52 years.[9][10]
Pathophysiology
The pathogenesis of granuloma faciale is not well-established. Some authors consider this skin disorder a variant of chronic cutaneous vasculitis, possibly resulting from a localized Arthus phenomenon.[11]
Histopathology
Specific histopathologic features have not been clearly defined for granuloma faciale. The most frequently reported findings include a Grenz zone, dermal infiltration of neutrophils, and telangiectasia. Inflammatory infiltrates in the dermis are typically separated from the overlying epidermis by a narrow Grenz zone of uninvolved dermis. Dilated follicular ostia and follicular plugs are commonly observed. The dermal infiltrates are predominantly perivascular and composed mainly of neutrophils, lymphocytes, and plasma cells, with frequent eosinophil involvement.
Vascular alterations are common and consist primarily of perivascular infiltrates that may extend into vessel walls and produce leukocytoclasia. Necrotizing vasculitis is rarely observed. The presence of hemosiderin and red blood cell extravasation supports underlying vascular injury.
Direct immunofluorescence is not uniformly positive and lacks pathognomonic specificity for granuloma faciale. When present, findings include granular perivascular or basement membrane zone deposits of immunoglobulin G, with less intense deposits of immunoglobulin M, and, occasionally, immunoglobulin A, and complement components 3 and 1q.
History and Physical
Granuloma faciale typically presents as a chronic, progressive, asymptomatic, isolated, well-defined reddish-brown to violaceous papule, nodule, or plaque with follicular accentuation and telangiectasia. The most commonly affected sites are the face and other sun-exposed areas. Dermoscopy serves as a valuable tool in clinical evaluation and often mirrors both the clinical and histologic features of granuloma faciale. The most frequently observed dermoscopic findings include linear arborizing vessels, dilated follicular openings, and brown dots or globules. These brown structures are thought to correspond to hemosiderin deposition.[12][13]
Evaluation
Granuloma faciale follows a progressive, chronic course characterized by recurrent acute exacerbations rather than distinct acute and chronic phases. Consequently, histopathologic findings often reflect overlapping features of both acute and chronic inflammation, making it difficult to assess chronicity based solely on tissue examination. Laboratory evaluation is generally unremarkable, although mild peripheral eosinophilia may be observed. While granuloma faciale is a benign condition, spontaneous resolution is uncommon, and most cases require therapeutic intervention. Currently available treatments carry a significant risk of recurrence.[14][15]
Treatment / Management
Topical Treatments
Topical therapies are considered the 1st-line treatment for granuloma faciale, with calcineurin inhibitors, particularly tacrolimus, being the most frequently used agents. Calcineurin inhibitors reduce T-cell activation and downregulate interleukin 2 expression. Tacrolimus 0.1% ointment, applied twice daily, appears to be the most effective initial option.[16][17][18][19][20] However, lesion clearance may require prolonged therapy, with most cases responding within 2 to 6 months of continuous treatment.[21][22][23][24](B3)
Topical or intralesional corticosteroids have also demonstrated variable effectiveness in treating granuloma faciale. Intralesional corticosteroids may be combined with cryotherapy for enhanced results. The most commonly reported regimen involves triamcinolone acetonide at concentrations of 5 to 20 mg/mL, administered weekly or monthly.[25][26][27][28][29](B3)
Additional treatment approaches have included topical dapsone 5% gel, which has shown favorable outcomes in isolated case reports.[30] Intralesional rituximab at a dose of 10 mg/mL once monthly has been used in 3 reported cases, with relatively good responses.[31][32] More recently, adjunct therapy with topical Janus kinase inhibitors, such as ruxolitinib, has been explored for refractory cases, with promising results in emerging case studies.[33][34](B3)
Systemic Therapies
Systemic treatments have been employed in the management of granuloma faciale, particularly in refractory or widespread cases. Dapsone, administered at doses ranging from 50 to 150 mg per day, has demonstrated clinical effectiveness.[35][36][37] Although the exact mechanism of action remains unclear, dapsone is known to exert anti-inflammatory, antimicrobial, and antiprotozoal effects. The drug's anti-inflammatory properties may involve multiple mechanisms, including inhibition of prostaglandin synthesis and production, as well as prevention of neutrophil extravasation at the lesional site.[38][39](B3)
Systemic corticosteroids have also been used, though responses are typically partial and inconsistent.[40][41] Clofazimine, an anti-leprosy agent with anti-inflammatory and anti-proliferative effects on lymphocytes and carcinoma cells, has received limited attention in the treatment of granuloma faciale. A dose of 300 mg per day has shown favorable outcomes in a few cases after 3 to 5 months of treatment.[42][43](B2)
Surgery and Other Procedures
Several procedural and surgical therapies have been explored for the treatment of granuloma faciale, particularly in cases resistant to topical or systemic agents. Cryotherapy using liquid nitrogen has been reported as an effective standalone option.[44]
Laser therapy has also been widely discussed in the literature, with outcomes varying based on lesion characteristics, laser type, and operator experience. The pulsed dye laser targets oxyhemoglobin within blood vessels and has demonstrated favorable cosmetic outcomes, particularly for superficial lesions. Multiple treatment sessions are often required, typically spaced 2 to 4 months apart. Compared to other laser modalities, the pulsed dye laser is associated with a lower risk of scarring, although pain during the procedure and posttreatment bruising are common side effects.[45][46][47](A1)
Other lasers used in the treatment of granuloma faciale include the potassium-titanyl-phosphate 532-nm laser, which has shown good results following 5 to 10 days of daily treatment without significant scarring. The carbon dioxide laser has also been employed in select cases.[48][49][50][51] The argon laser, operating at 480 to 520 nm, offers more selective targeting of oxyhemoglobin than the carbon dioxide laser but may result in greater nonspecific tissue injury due to wider heat diffusion.[52][53](B3)
Additional therapies include phototherapy, particularly topical psoralen combined with ultraviolet A, and surgical approaches such as excision with or without grafting. Dermabrasion has also been reported as a treatment option.[54][55](B3)
Differential Diagnosis
Several cutaneous conditions can mimic the clinical presentation of granuloma faciale. The differential diagnosis includes sarcoidosis, discoid lupus erythematosus, rosacea, mycobacterial infections, deep fungal infections of the skin, cutaneous lymphoma, and basal cell carcinoma.[56]
Erythema elevatum diutinum (EED) is a key histopathologic differential diagnosis, as both conditions may display overlapping features such as fibrosing vasculitis.[57] A common pathogenic mechanism has been proposed for both EED and granuloma faciale. The primary distinction is clinical. EED typically presents as multiple lesions on extensor surfaces, whereas granuloma faciale usually manifests as a solitary lesion on the face. Diagnostic difficulty arises when EED presents on the face or when granuloma faciale involves extrafacial sites. A dense eosinophilic infiltrate strongly supports a diagnosis of granuloma faciale, while granulomatous nodules may be observed in EED.
Additionally, EED is often associated with underlying systemic conditions, including hematologic disorders, autoimmune diseases, HIV infection, other infections, and insect bites. In contrast, granuloma faciale is rarely linked to systemic disease.[58]
Prognosis
Granuloma faciale follows a benign but persistent course, with spontaneous resolution occurring in fewer than 10% of cases. Lesions often persist for years to decades, and treatment is frequently necessary to control progression or achieve remission. Recurrence rates are high, reported in 50% to 60% of cases, particularly following the cessation of therapy with superficial modalities such as topical corticosteroids or cryotherapy.
Although the condition is primarily localized to the face, extrafacial lesions occur in approximately 10% to 15% of cases, most often on sun-exposed areas such as the scalp, trunk, or extremities. Granuloma faciale carries no risk of systemic involvement or malignant transformation and shows no association with systemic vasculitis or autoimmune disease.
Newer therapeutic approaches, including topical calcineurin inhibitors such as tacrolimus, pulsed dye laser, and intralesional corticosteroids, have shown success in inducing remission, with some reports documenting partial or complete clearance in up to 70% of treated patients. The long-term prognosis is favorable with respect to morbidity, although the cosmetic burden and refractory nature in some cases require ongoing management and patient counseling.
Complications
Granuloma faciale, though histopathologically suggestive of leukocytoclastic vasculitis, is confined to the dermis and lacks systemic vasculitic involvement. Complications are therefore primarily local and cosmetic rather than systemic. The most significant complication is persistent disfigurement, particularly when lesions are nodular, hypertrophic, or located in cosmetically sensitive areas such as the nasal dorsum, cheeks, or forehead.
Chronic lesions may develop telangiectasia, postinflammatory hyperpigmentation, atrophy, or scarring, especially after repeated interventions including intralesional corticosteroids, cryotherapy, or ablative laser procedures. Aggressive treatment in recalcitrant cases may lead to cutaneous thinning or hypopigmentation, which can contribute to psychological distress and reduced quality of life. Secondary bacterial infection is uncommon but may occur in ulcerated or excoriated lesions.
Granuloma faciale does not involve internal organs, progress to systemic vasculitis, or undergo malignant transformation—features that distinguish it from other vasculitic or granulomatous dermatoses. However, the refractory course, with frequent relapse despite treatment, often necessitates long-term dermatologic follow-up and interprofessional collaboration, particularly in patients with extensive or cosmetically deforming disease. Early recognition and careful selection of therapy can help prevent permanent sequelae.
Deterrence and Patient Education
Deterrence of granuloma faciale is limited, as no definitive environmental, infectious, or genetic trigger has been linked to its pathogenesis. Nonetheless, patient education plays a central role in long-term management. Patients should understand that granuloma faciale is a benign, chronic cutaneous condition, typically localized to the face, and carries no risk of systemic involvement or malignant transformation. Although asymptomatic in most cases, lesions may persist for years and often require repeated intervention due to a high rate of recurrence following treatment.
Education should emphasize the importance of adherence to prescribed therapies, including topical agents, laser treatments, and intralesional injections, as well as the need for regular follow-up to assess response and minimize long-term disfigurement. Patients must be cautioned against self-manipulation and unsupervised use of topical corticosteroids, which may exacerbate telangiectasia or lead to atrophy. Psychological support may be appropriate in individuals experiencing distress related to the cosmetic burden, particularly in cases involving facial or treatment-resistant lesions. Camouflage techniques may also be offered as an adjunct to medical therapy. Given the refractory nature of the disease, setting realistic expectations about treatment outcomes and the potential for relapse is critical to maintaining patient engagement and therapeutic success.
Enhancing Healthcare Team Outcomes
Primary care providers and nurse practitioners who encounter persistent facial lesions should refer patients to a dermatologist for comprehensive evaluation. Collaboration with a dermatopathologist is essential to ensure diagnostic accuracy, given the broad range of clinical and histologic differentials associated with granuloma faciale. An interprofessional team that includes physicians, nurse practitioners, physician assistants, and pharmacists provides the best framework for effective case management and coordinated patient care. Surgical treatment, particularly for facial lesions, should be planned in consultation with a plastic surgeon to optimize functional and cosmetic outcomes.
References
Wigley JE. Eosinophilic Granuloma. ? Sarcoid of Boeck. Proceedings of the Royal Society of Medicine. 1945 Jan:38(3):125-6 [PubMed PMID: 19992999]
Oliveira CC, Ianhez PE, Marques SA, Marques ME. Granuloma faciale: clinical, morphological and immunohistochemical aspects in a series of 10 patients. Anais brasileiros de dermatologia. 2016 Nov-Dec:91(6):803-807. doi: 10.1590/abd1806-4841.20164628. Epub [PubMed PMID: 28099604]
Ortonne N, Wechsler J, Bagot M, Grosshans E, Cribier B. Granuloma faciale: a clinicopathologic study of 66 patients. Journal of the American Academy of Dermatology. 2005 Dec:53(6):1002-9 [PubMed PMID: 16310061]
Level 2 (mid-level) evidenceDeen J, Moloney TP, Muir J. Extrafacial Granuloma Faciale: A Case Report and Brief Review. Case reports in dermatology. 2017 May-Aug:9(2):79-85. doi: 10.1159/000477960. Epub 2017 Jul 13 [PubMed PMID: 28868005]
Level 3 (low-level) evidenceMa S, Liu H, Zhang F. Diffuse granuloma faciale. International journal of dermatology. 2023 Jul:62(7):969-970. doi: 10.1111/ijd.16550. Epub 2022 Dec 18 [PubMed PMID: 36529934]
Lindhaus C, Elsner P. Granuloma Faciale Treatment: A Systematic Review. Acta dermato-venereologica. 2018 Jan 12:98(1):14-18. doi: 10.2340/00015555-2784. Epub [PubMed PMID: 28880343]
Level 1 (high-level) evidenceNigar E, Dhillon R, Carr E, Matin RN. Eosinophilic angiocentric fibrosis and extrafacial granuloma faciale. Histopathology. 2007 Nov:51(5):729-31 [PubMed PMID: 17927606]
Level 3 (low-level) evidenceGoldner R, Sina B. Granuloma faciale: the role of dapsone and prior irradiation on the cause of the disease. Cutis. 1984 May:33(5):478-9, 482 [PubMed PMID: 6478871]
Level 3 (low-level) evidenceMarcoval J, Moreno A, Peyr J. Granuloma faciale: a clinicopathological study of 11 cases. Journal of the American Academy of Dermatology. 2004 Aug:51(2):269-73 [PubMed PMID: 15280847]
Level 3 (low-level) evidenceRadin DA, Mehregan DR. Granuloma faciale: distribution of the lesions and review of the literature. Cutis. 2003 Sep:72(3):213-9; quiz 208 [PubMed PMID: 14533833]
Barnadas MA, Curell R, Alomar A. Direct immunofluorescence in granuloma faciale: a case report and review of literature. Journal of cutaneous pathology. 2006 Jul:33(7):508-11 [PubMed PMID: 16872475]
Level 3 (low-level) evidenceLallas A, Sidiropoulos T, Lefaki I, Tzellos T, Sotiriou E, Apalla Z. Photoletter to the editor: Dermoscopy of granuloma faciale. Journal of dermatological case reports. 2012 Jun 30:6(2):59-60. doi: 10.3315/jdcr.2012.1101. Epub [PubMed PMID: 22826723]
Level 3 (low-level) evidenceChauhan P, Meena D. Dermoscopy of Granuloma Faciale in the Skin of Color. Indian dermatology online journal. 2022 Sep-Oct:13(5):686-687. doi: 10.4103/idoj.idoj_532_21. Epub 2022 Sep 5 [PubMed PMID: 36304640]
Ludwig E, Allam JP, Bieber T, Novak N. New treatment modalities for granuloma faciale. The British journal of dermatology. 2003 Sep:149(3):634-7 [PubMed PMID: 14511001]
Level 3 (low-level) evidenceTomson N, Sterling JC, Salvary I. Granuloma faciale treated successfully with topical tacrolimus. Clinical and experimental dermatology. 2009 Apr:34(3):424-5. doi: 10.1111/j.1365-2230.2008.02874.x. Epub 2008 Oct 22 [PubMed PMID: 19175788]
Level 3 (low-level) evidenceLima RS, Maquiné GÁ, Silva Junior RC, Schettini AP, Santos M. Granuloma faciale: a good therapeutic response with the use of topical tacrolimus. Anais brasileiros de dermatologia. 2015 Sep-Oct:90(5):735-7. doi: 10.1590/abd1806-4841.20153339. Epub [PubMed PMID: 26560220]
Cecchi R, Pavesi M, Bartoli L, Brunetti L. Topical tacrolimus in the treatment of granuloma faciale. International journal of dermatology. 2010 Dec:49(12):1463-5. doi: 10.1111/j.1365-4632.2009.04317.x. Epub [PubMed PMID: 21091691]
Level 3 (low-level) evidencePérez-Robayna N, Rodríguez-García C, González-Hernández S, Sánchez R, Guimerá F, Sáez M. Successful response to topical tacrolimus for a granuloma faciale in an elderly patient. Dermatology (Basel, Switzerland). 2009:219(4):359-60. doi: 10.1159/000243806. Epub 2009 Oct 1 [PubMed PMID: 19797891]
Level 3 (low-level) evidenceMitchell D. Successful treatment of granuloma faciale with tacrolimus. Dermatology online journal. 2004 Oct 15:10(2):23 [PubMed PMID: 15530313]
Level 3 (low-level) evidenceEetam I, Ertekin B, Unal I, Alper S. Granuloma faciale: Is it a new indication for pimecrolimus? A case report. The Journal of dermatological treatment. 2006:17(4):238-40 [PubMed PMID: 16971320]
Level 3 (low-level) evidenceMarcoval J, Moreno A, Bordas X, Peyrí J. Granuloma faciale: treatment with topical tacrolimus. Journal of the American Academy of Dermatology. 2006 Nov:55(5 Suppl):S110-1 [PubMed PMID: 17052523]
Level 3 (low-level) evidenceJedlicková H, Feit J, Semrádová V. Granuloma faciale successfully treated with topical tacrolimus: a case report. Acta dermatovenerologica Alpina, Pannonica, et Adriatica. 2008 Mar:17(1):34-6 [PubMed PMID: 18454269]
Level 3 (low-level) evidencePatterson C, Coutts I. Granuloma faciale successfully treated with topical tacrolimus. The Australasian journal of dermatology. 2009 Aug:50(3):217-9. doi: 10.1111/j.1440-0960.2009.00543.x. Epub [PubMed PMID: 19659988]
Level 3 (low-level) evidenceDourmishev L, Ouzounova-Raykova V, Broshtilova V, Miteva L. Granuloma faciale effectively treated with topical pimecrolimus. Acta dermatovenerologica Croatica : ADC. 2014:22(4):305-7 [PubMed PMID: 25580794]
Level 3 (low-level) evidenceDowlati B, Firooz A, Dowlati Y. Granuloma faciale: successful treatment of nine cases with a combination of cryotherapy and intralesional corticosteroid injection. International journal of dermatology. 1997 Jul:36(7):548-51 [PubMed PMID: 9268759]
Level 3 (low-level) evidenceZargari O. Disseminated granuloma faciale. International journal of dermatology. 2004 Mar:43(3):210-2 [PubMed PMID: 15009395]
Level 3 (low-level) evidenceVerma R, Das AL, Vaishampayan SS, Vaidya S. Keloidal granuloma faciale with extrafacial lesions. Indian journal of dermatology, venereology and leprology. 2005 Sep-Oct:71(5):345-7 [PubMed PMID: 16394461]
Level 3 (low-level) evidenceMashood AA, Simeen-ber-Rahman. Granuloma faciale -- an unusual presentation. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2006 Apr:16(4):296-7 [PubMed PMID: 16624198]
Level 3 (low-level) evidenceDe D, Kanwar AJ, Radotra BD, Gupta S. Extrafacial granuloma faciale: report of a case. Journal of the European Academy of Dermatology and Venereology : JEADV. 2007 Oct:21(9):1284-6 [PubMed PMID: 17894740]
Level 3 (low-level) evidenceBabalola O, Zhang J, Kristjansson A, Whitaker-Worth D, McCusker M. Granuloma faciale treated with topical dapsone: a case report. Dermatology online journal. 2014 Aug 17:20(8):. pii: 13030/qt9q7520rx. Epub 2014 Aug 17 [PubMed PMID: 25148282]
Level 3 (low-level) evidenceMorgado-Carrasco D, Giavedoni P, Mascaró JM Jr, Iranzo P. Assessment of Treatment of Refractory Granuloma Faciale With Intralesional Rituximab. JAMA dermatology. 2018 Nov 1:154(11):1312-1315. doi: 10.1001/jamadermatol.2018.2681. Epub [PubMed PMID: 30193300]
Joly E, Duval-Modeste A, Sabatier R, Arhant G, Cellier L, Mouthon M, Comoz F, Joly P, Dompmartin A. Intralesional rituximab treatment for atypical refractory granuloma faciale. Annales de dermatologie et de venereologie. 2021 Dec:148(4):272-274. doi: 10.1016/j.annder.2021.06.001. Epub 2021 Aug 26 [PubMed PMID: 34456047]
Chen A, Harview CL, Rand SE, Harms JL. Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor. JAAD case reports. 2023 Mar:33():91-94. doi: 10.1016/j.jdcr.2023.01.016. Epub 2023 Jan 30 [PubMed PMID: 36895509]
Level 3 (low-level) evidenceWong A, Stahly S, Kieffer J, Dunn C, Nathoo R. Topical ruxolitinib for the treatment of granuloma faciale. JAAD case reports. 2023 Jun:36():73-74. doi: 10.1016/j.jdcr.2023.04.013. Epub 2023 Apr 24 [PubMed PMID: 37250006]
Level 3 (low-level) evidenceHolme SA, Laidler P, Holt PJ. Concurrent granuloma faciale and eosinophilic angiocentric fibrosis. The British journal of dermatology. 2005 Oct:153(4):851-3 [PubMed PMID: 16181479]
Level 3 (low-level) evidenceGupta L, Naik H, Kumar NM, Kar HK. Granuloma faciale with extrafacial involvement and response to tacrolimus. Journal of cutaneous and aesthetic surgery. 2012 Apr:5(2):150-2. doi: 10.4103/0974-2077.99463. Epub [PubMed PMID: 23060713]
Level 3 (low-level) evidenceFumo G, Patta F, Milo C, Pilloni L, Atzori L. A nose for trouble. Diagnosis: Granuloma faciale. Indian journal of dermatology, venereology and leprology. 2015 Jan-Feb:81(1):93-4. doi: 10.4103/0378-6323.148604. Epub [PubMed PMID: 25566920]
Level 3 (low-level) evidenceZampeli E, Moutsopoulos HM. Dapsone: an old drug effective for subacute cutaneous lupus erythematosus. Rheumatology (Oxford, England). 2019 May 1:58(5):920-921. doi: 10.1093/rheumatology/key434. Epub [PubMed PMID: 30615176]
Pfeiffer C, Wozel G. Dapsone and sulfones in dermatology: overview and update. Journal of the American Academy of Dermatology. 2003 Feb:48(2):308-9 [PubMed PMID: 12582416]
Level 3 (low-level) evidenceYuan C, Bu W, Chen X, Gu H. A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide. Postepy dermatologii i alergologii. 2018 Feb:35(1):109-112. doi: 10.5114/ada.2018.73170. Epub 2018 Feb 20 [PubMed PMID: 29599681]
Level 3 (low-level) evidenceSand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatologic therapy. 2015 May-Jun:28(3):158-65. doi: 10.1111/dth.12222. Epub 2015 Mar 3 [PubMed PMID: 25731720]
Level 2 (mid-level) evidenceWollina U, Karte K, Geyer A, Stuhlert A, Bocker T. Clofazimine in inflammatory facial dermatosis--granuloma faciale and lipogranulomatosis subcutanea (Rothmann-Makai). Acta dermato-venereologica. 1996 Jan:76(1):77-9 [PubMed PMID: 8721503]
Level 3 (low-level) evidenceGómez-de la Fuente E, del Rio R, Rodriguez M, Guerra A, Rodriguez-Peralto JL, Iglesias L. Granuloma faciale mimicking rhinophyma: response to clofazimine. Acta dermato-venereologica. 2000 Mar-Apr:80(2):144 [PubMed PMID: 10877139]
Level 3 (low-level) evidencePanagiotopoulos A, Anyfantakis V, Rallis E, Chasapi V, Stavropoulos P, Boubouka C, Katsambas A. Assessment of the efficacy of cryosurgery in the treatment of granuloma faciale. The British journal of dermatology. 2006 Feb:154(2):357-60 [PubMed PMID: 16433810]
Fikrle T, Pizinger K. Granuloma Faciale treated with 595-nm pulsed dye laser. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2011 Jan:37(1):102-4. doi: 10.1111/j.1524-4725.2010.01823.x. Epub 2010 Nov 11 [PubMed PMID: 21070474]
Level 3 (low-level) evidenceHruza GJ, Ammirati CT. Granuloma faciale treated with 595-nm pulsed dye laser. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2011 Jul:37(7):1060-1. doi: 10.1111/j.1524-4725.2011.02035.x. Epub [PubMed PMID: 21711410]
Level 3 (low-level) evidenceErceg A, de Jong EM, van de Kerkhof PC, Seyger MM. The efficacy of pulsed dye laser treatment for inflammatory skin diseases: a systematic review. Journal of the American Academy of Dermatology. 2013 Oct:69(4):609-615.e8. doi: 10.1016/j.jaad.2013.03.029. Epub 2013 May 24 [PubMed PMID: 23711766]
Level 1 (high-level) evidenceChung WK, Park GH, Kim CH, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK. Keloidal granuloma faciale after CO2 laser treatment for melanocytic naevus. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009 May:23(5):611-2 [PubMed PMID: 19415815]
Level 3 (low-level) evidenceWheeland RG, Ashley JR, Smith DA, Ellis DL, Wheeland DN. Carbon dioxide laser treatment of granuloma faciale. The Journal of dermatologic surgery and oncology. 1984 Sep:10(9):730-3 [PubMed PMID: 6434613]
Level 3 (low-level) evidencePrideaux A, Hitchens E, Thomas K, Wainman H, Keith D. A case of resistant granuloma faciale successfully treated with ablative fractional carbon dioxide laser. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology. 2024 Nov 16:26(5-8):136-137. doi: 10.1080/14764172.2024.2421019. Epub 2024 Oct 29 [PubMed PMID: 39471333]
Level 3 (low-level) evidenceBakkour W, Madan V. Rhinophyma-like granuloma faciale successfully treated with carbon dioxide laser. The British journal of dermatology. 2014 Feb:170(2):474-5. doi: 10.1111/bjd.12649. Epub [PubMed PMID: 24111815]
Level 3 (low-level) evidenceApfelberg DB, Druker D, Maser MR, Lash H, Spence B Jr, Deneau D. Granuloma faciale. Treatment with the argon laser. Archives of dermatology. 1983 Jul:119(7):573-6 [PubMed PMID: 6859900]
Level 3 (low-level) evidenceCheung ST, Lanigan SW. Granuloma faciale treated with the pulsed-dye laser: a case series. Clinical and experimental dermatology. 2005 Jul:30(4):373-5 [PubMed PMID: 15953073]
Level 3 (low-level) evidenceHudson LD. Granuloma faciale: treatment with topical psoralen and UVA. Journal of the American Academy of Dermatology. 1983 Apr:8(4):559 [PubMed PMID: 6853786]
Level 3 (low-level) evidenceBergfeld WF, Scholes HT, Roenigk HH Jr. Granuloma faciale--treatment by dermabrasion. Report of a case. Cleveland Clinic quarterly. 1970 Oct:37(4):215-8 [PubMed PMID: 5520807]
Level 3 (low-level) evidenceFrankel DH, Soltani K, Medenica MM, Rippon JW. Tinea of the face caused by Trichophyton rubrum with histologic changes of granuloma faciale. Journal of the American Academy of Dermatology. 1988 Feb:18(2 Pt 2):403-6 [PubMed PMID: 3343409]
Level 3 (low-level) evidenceFrantz R, Chukwuma O, Sokumbi O, Satcher K, Kallis P, Vincek V, Motaparthi K. Identifying histopathologic features of erythema elevatum diutinum and granuloma faciale. Journal of cutaneous pathology. 2022 Mar:49(3):323-326. doi: 10.1111/cup.14191. Epub 2022 Jan 4 [PubMed PMID: 34939211]
Ziemer M, Koehler MJ, Weyers W. Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? Journal of cutaneous pathology. 2011 Nov:38(11):876-83. doi: 10.1111/j.1600-0560.2011.01760.x. Epub 2011 Aug 23 [PubMed PMID: 21883365]